Results 21 to 30 of about 2,738 (166)
Urinary Neopterin and Microalbuminuria in Patients Treated by Low-density Lipoprotein Apheresis
Pteridines, 2005 Low-density lipoprotein (LDL)-apheresis is a method of extracorporeal elimination of LDL-cholesterol in patients with severe primary lipoprotein disorders.
Cermanová Melanie +8 more
doaj +1 more source
Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome [PDF]
Childhood Kidney Diseases, 2022 Dyslipidemia in nephrotic syndrome (NS) is often characterized by marked increases in the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and other lipoproteins, such as very low-density lipoprotein, intermediate-density ...
Hee Sun Baek
doaj +1 more source
LDL‐aférese no tratamento de hipercolesterolemia familiar: experiência do Hospital Santo António
Revista Portuguesa de Cardiologia, 2015 Resumo: Introdução: A hipercolesterolemia manifestada pelos níveis elevados de colesterol das lipoproteínas de baixa densidade constitui um fator de risco major para o desenvolvimento e progressão da doença aterosclerótica prematura.A adsorção direta de
Isabel Palma +8 more
doaj +1 more source
LDL-Apheresis: Technical and Clinical Aspects
The Scientific World Journal, 2012 The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) levels, and coronary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density
Rolf Bambauer +4 more
doaj +1 more source
Journal of Lipid Research, 1990 Low density lipoproteins (LDL) have the potential to serve as cell specific drug carriers. The LDL may be derived in large quantities from LDL-apheresis procedures.
HW Schultis +3 more
doaj +1 more source
Российский кардиологический журналThe article presents the up-to-date information on the effect of lipoprotein apheresis (LA) on atherosclerotic lesions. Some studies using modern diagnostic imaging techniques (such as intravascular ultrasound or magnetic resonance imaging) have clearly ...
Ulrich Julius +2 more
doaj +1 more source
LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
Российский кардиологический журнал, 2018 The first attempts to treat patients with homozygous familial hypercholesterolemia (HCH) were performed in the 60ies and 70ies using a total plasma exchange. Later on, more specific lipoprotein apheresis (LA) methods have been developed – the replacement
U. Julius, S. Tselmin, S. R. Bornstein
doaj +1 more source
Lipoprotein apheresis: an update
Clinical Lipidology, 2013 Since the 1980s, several lipoprotein apheresis methods that eliminate atherogenic lipoproteins (LDL and lipoprotein(a) [Lp(a)]) have been developed. These methods are based on the following principles: precipitation, adsorption and filtration. In Dresden (Germany), we started to perform extracorporeal treatment in 1990; in the 1980s we were working as ...
Ulrich. Julius +4 more
openaire +1 more source
Turkish Journal of Hematology, 2012 OBJECTIVE: The aim of our study is to discuss the efficacy of low-density lipoprotein-cholesterol (LDL-C) apheresis procedure using the cascade filtration system for pediatric patients with homozygous familial hypercholesterolemia (FH), and to clarify ...
Fatih Kardas +7 more
doaj +1 more source
Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis
Atherosclerosis Supplements, 2019 Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and a predictor of incident or recurrent cardiovascular events. Although Lp(a) was first described as
Klingel, Reinhard +9 more
openaire +3 more sources